Market: NMS |
Currency: USD
Address: 9350 Kirby Drive
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
📈 Marker Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.87
-
Upside/Downside from Analyst Target:
274.60%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.100000 |
- |
2023-01-27 |
- |
Stock split |
|
Total Amount for 2023: $0.100000 |
| 2016 |
- |
$0.083333 |
- |
2016-09-16 |
- |
Stock split |
|
Total Amount for 2016: $0.083333 |
📅 Earnings & EPS History for Marker Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 | -0.12 |
| 2025-08-14 | -0.29 |
| 2025-05-15 | -0.4 |
| 2025-03-31 | -0.42 |
| 2024-11-14 | -0.26 |
| 2024-08-14 | -0.25 |
| 2024-05-15 | -0.27 |
| 2023-03-22 | -3.27 |
| 2022-11-10 | -0.8 |
| 2022-08-11 | -1.1 |
| 2022-05-13 | -1.18 |
| 2022-03-17 | -1.1 |
| 2021-11-09 | -1.5 |
| 2021-08-10 | -1.3 |
| 2021-05-12 | -1.6 |
| 2021-03-09 | -1.8 |
| 2020-11-09 | -1.6 |
| 2020-08-10 | -1.4 |
| 2020-05-11 | -1.4 |
| 2020-03-12 | -1.1 |
| 2019-11-12 | -1.2 |
| 2019-08-08 | -1.2 |
| 2019-05-10 | -1.2 |
| 2019-03-15 | -4.3 |
| 2018-11-13 | -3.2 |
📰 Related News & Research
No related articles found for "marker therapeutics".
